Briefing
Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence.
Personalized assays targeting 16 variants chosen from the primary tumor whole exome were used on plasma collected every 6 months for up to 4 years to detect ctDNA before metastatic breast cancer recurrence. The abstract does not name a commercial assay.
- Design: Evidence level 3
- Assay: Not named in the abstract
Clinical Cancer ResearchPubMed 30992300DOI 10.1158/1078-0432.CCR-18-3663